PROCURE Prostate Cancer Biobank, Canada

Certification Status: Invite Member

Registration Status: Completed

Objective: PROCURE has a Prostate cancer Biobank containing biospecimens, coupled to both clinico-pathological and epidemiologic data. This Biobank results from collaboration of urologists, scientists, pathologists and research personnel from four university hospitals in QuÃ©bec province. Newly diagnosed patients undergoing radical prostatectomy agreed to sign an ethically approved consent form to participate in the project and responded to a detailed questionnaire on socio-demographic data and lifestyle habits. Blood, urine, and prostate tissues are obtained, systematically processed in a timely fashion and banked on site using standardized operating procedures. Blood, urine and clinical data are also collected at follow-up visits. The Biobank has now more than 2 000 participants and had registered more than 3000 follow-up visits.

Registered Biobank Name	PROCURE Prostate Cancer Biobank
Biobank Leader	Dr Alain Bergeron; Ms. Ginette McKercher
Country	Canada
Email for biobank inquiries	alain.bergeron@crchudequebec.ulaval.ca
Principal Investigator	Dr Armen Aprikian, Dr Fred Saad, Dr Michel Carmel, Dr Louis Lacombe
Website	https://www.procure.ca/en/what-we-do/procure-biobank/
User Type Mono: A biobank that supports a specific research project, may have few staff members, a small-scale accrual scope with little to no initial intention of releasing or distributing biospecimens to secondary parties Oligo: A biobank that supports several research groups or clinical trials, may or may not be designed to release biospecimens outside their collaborative group Poly: A biobank that has generally a larger accrual scope, resources, and multiple users outside the biobank proper	Poly - Collection aimed at supporting undetermined, multiple users with ethics approved research projects, through a defined access/application mechanism.

Biospecimen Collected:

Cohort Highlights

100 cases Next Generation Sequencing assay to detect all classes of genetic variant in Lung Cancer using a single Diagnostic test.
200 cases Colorectal TMA for QC purposes in support of study of tumor infiltrating lymphocytes in ovarian cancer tissues.
Build 300 cases breast cancer TMA containing primary tumour and matched metastatic LN for various subtypes (luminal, HER2, Triple negative). Start with Triple negatives.
125 cases Breast tumour and metastatic lymph nodes in breast cancer cases with outcomes of metastasis to lung or bone.
100 cases of rare tumours - fibrolamellar hepatocellular carcinoma. FFPE, frozen, BC.
200 cases of FFPE tissue sections from breast, lung adenocarcinoma, and lung squamous cell carcinoma with matching normal tissue (only pathology data requested).